Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
暂无分享,去创建一个
[1] J. Ahn,et al. Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment , 2020, Oncoimmunology.
[2] Jeffrey E. Lee,et al. B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.
[3] J. Wargo,et al. B cells are associated with survival and immunotherapy response in sarcoma , 2020, Nature.
[4] D. Schadendorf,et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma , 2020, Nature.
[5] Shuhang Wang,et al. TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer , 2019, Cancer Immunology Research.
[6] J. Gartner,et al. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. , 2019, The Journal of clinical investigation.
[7] E. Wherry,et al. Defining ‘T cell exhaustion’ , 2019, Nature Reviews Immunology.
[8] M. Rizzo,et al. Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients , 2019, Cancer Immunology, Immunotherapy.
[9] Ho Yun Lee,et al. Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] David L Rimm,et al. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. , 2019, JAMA oncology.
[11] B. Cho,et al. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] G. Kochan,et al. Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy , 2019, EMBO molecular medicine.
[13] S. Mallal,et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis , 2019, Nature Medicine.
[14] Hiromasa Morikawa,et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer , 2019, Proceedings of the National Academy of Sciences.
[15] E. Wherry,et al. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. , 2019, Annual review of immunology.
[16] P. Hwu,et al. IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy , 2019, Cancer Immunology Research.
[17] J. Sugisaka,et al. Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer , 2019, JAMA oncology.
[18] G. Linette,et al. A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma , 2019, Nature Medicine.
[19] J. Ahn,et al. The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors , 2019, Clinical Cancer Research.
[20] S. Ha,et al. The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer. , 2019, American journal of respiratory and critical care medicine.
[21] R. Sullivan,et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.
[22] Edmond J. Breen,et al. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy , 2018, Clinical Cancer Research.
[23] D. Planchard,et al. Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy , 2018, JAMA oncology.
[24] J. Soria,et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management , 2018, Nature Reviews Clinical Oncology.
[25] J. Lunceford,et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.
[26] A. Mammen,et al. Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1 , 2018, Annals of the rheumatic diseases.
[27] K. Hargadon,et al. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. , 2018, International immunopharmacology.
[28] E. Jaffee,et al. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. , 2018, JCI insight.
[29] Tao Jiang,et al. Heterogeneity of PD‐L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma , 2018, Clinical lung cancer.
[30] F. Prósper,et al. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity , 2018, Haematologica.
[31] C. Klein,et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade , 2018, Nature Network Boston.
[32] E. Wherry,et al. Non-conventional Inhibitory CD4+Foxp3-PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. , 2018, Cancer cell.
[33] M. Fehlings,et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates , 2018, Nature.
[34] Jedd D. Wolchok,et al. Cancer immunotherapy using checkpoint blockade , 2018, Science.
[35] S. Baxi,et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis , 2018, British Medical Journal.
[36] P. Hegde,et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial , 2018, The Lancet.
[37] A. Kamphorst,et al. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. , 2018, Annual review of medicine.
[38] Matthew D. Hellmann,et al. Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.
[39] Reinhard Dummer,et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy , 2018, Nature Network Boston.
[40] Aaron M. Newman,et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade , 2018, The Journal of clinical investigation.
[41] J. Cho. Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles , 2017, Immune network.
[42] P. Hofman. PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted? , 2017, Expert review of molecular diagnostics.
[43] K. Kerr,et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] V. Servois,et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] W. Miller,et al. Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade. , 2017, The New England journal of medicine.
[46] J. Bluestone,et al. Is autoimmunity the Achilles' heel of cancer immunotherapy? , 2017, Nature Medicine.
[47] G. Sica,et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients , 2017, Proceedings of the National Academy of Sciences.
[48] Jedd D. Wolchok,et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.
[49] Razelle Kurzrock,et al. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate , 2017, Clinical Cancer Research.
[50] S. Culine,et al. Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.
[51] J. Wargo,et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.
[52] M. Millward,et al. Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity , 2017, Nature Reviews Drug Discovery.
[53] C. Rudin,et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[54] J. Radford. Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.
[55] Charles Ferté,et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.
[56] J. Seidman,et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.
[57] M. Vetizou,et al. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. , 2016, Immunity.
[58] J. Wolchok,et al. Targeting T Cell Co-receptors for Cancer Therapy. , 2016, Immunity.
[59] Antoni Ribas,et al. The “cancer immunogram” , 2016, Science.
[60] J. Gartner,et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients , 2016, Nature Medicine.
[61] T. Fleisher. Immune Dysregulation in Human Subjects With Heterozygous Germline Mutations in CTLA4 , 2015, Pediatrics.
[62] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[63] E. Wherry,et al. Molecular and cellular insights into T cell exhaustion , 2015, Nature Reviews Immunology.
[64] Razelle Kurzrock,et al. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.
[65] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[66] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[67] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[68] T. Nomura,et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. , 2009, Immunity.
[69] Thomas Korn,et al. IL-17 and Th17 Cells. , 2009, Annual review of immunology.
[70] P. Tak,et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.
[71] V. Kuchroo,et al. TH-17 cells in the circle of immunity and autoimmunity , 2007, Nature Immunology.
[72] P. Santamaria,et al. CD8+ T cells in autoimmunity. , 2005, Current opinion in immunology.
[73] P. Lipsky. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity , 2001, Nature Immunology.
[74] J. Altman,et al. Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function , 1998, The Journal of experimental medicine.
[75] R. Zinkernagel,et al. Induction and Exhaustion of Lymphocytic Choriomeningitis Virus–specific Cytotoxic T Lymphocytes Visualized Using Soluble Tetrameric Major Histocompatibility Complex Class I–Peptide Complexes , 1998, The Journal of experimental medicine.
[76] C. Marquette,et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[77] Shimon Sakaguchi,et al. Regulatory T cells exert checks and balances on self tolerance and autoimmunity , 2010, Nature Immunology.